Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aquestive Therapeutics, Inc.AQST · Entity 5276 | SVP, Regulatory Affairs | May 15, 2026 | May 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aquestive Therapeutics, Inc.
Report date May 15, 2026 · Filed May 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 273,200 |
Reported balance
After 2026-05-15 transaction · row 1
1 source rowRow 1 · 2026-05-15 · Tax withholding · Disposed 1,667 · Balance 273,200 F1: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 15, 2026 Filed May 18, 2026 16:36 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 1,667 | $4.17 | $6,951.39 |
DisclosureSEC source: 0001214659-26-006527 · marketforms-73191.xml · nonDerivative · entry 1 Cioffi Melina · CIK 0002066841 · SVP, Regulatory Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 273,200 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Read SEC document |
| March 10, 2026 Filed Mar 11, 2026 16:52 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | SaleCommon Stock | 25,311 | $4.17 | $105,622.80 |
DisclosureSEC source: 0001214659-26-003144 · marketforms-72465.xml · nonDerivative · entry 2 Cioffi Melina · CIK 0002066841 · SVP, Regulatory Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 274,867 F2 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $4.17 to $4.32. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 16:52 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 75,000 | $4.29 Strike: $4.29 | $321,750.00 |
DisclosureSEC source: 0001214659-26-003144 · marketforms-72465.xml · derivative · entry 3 Cioffi Melina · CIK 0002066841 · SVP, Regulatory Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2036-03-09 F4 · derivative.exercise_date: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 16:52 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-26-003144 · marketforms-72465.xml · nonDerivative · entry 1 Cioffi Melina · CIK 0002066841 · SVP, Regulatory Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,178 F1 · shares: The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 15:39 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 2,083 | $5.93 | $12,352.19 |
DisclosureSEC source: 0001214659-25-017591 · marketforms-71360.xml · nonDerivative · entry 1 Cioffi Melina · CIK 0002066841 · SVP, Regulatory Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,178 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Read SEC document |
| May 15, 2025 Filed May 15, 2025 16:59 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-25-007749 · marketforms-69454.xml · nonDerivative · entry 1 Cioffi Melina · CIK 0002066841 · SVP, Regulatory Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 202,261 F1 · shares: The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.